Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00122317 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Hemoglobinuria, Nocturnal

Interventions

DRUG: eculizumab

Sponsor

Alexion Pharmaceuticals, Inc.